2019

Stefan Sowa has been appointed as CEO of Endovascular Development AB (Endovab®). He most recently served as CEO of Novus Scientific AB.
Sowa has held leading positions in the life science sector for more than 25 years. During his six years at Novus the company became a manufacturing establishment approved according to ISO13485 and GMP with sales in 27 countries of surgical implant products. Before his time at Novus he was production manager for 10 years for cardiovascular products at Radi Medical Systems AB / St Jude.
His many roles have given Sowa broad experience of growing knowledge-intensive companies in the health care sector.
“Endovab’s proprietary arterial anchoring technology has a great potential in the growing market of endovascular tools and the established clinical experience and network is a fantastic foundation to build a successful company”, says Sowa.
ARCHIVE
LATEST NEWS
- STEFAN SOWA APPOINTED AS CEO
- THE GUIDEWIRE THAT ALLOWS TENSION
- Fenestrated aortic arch repair, from a pure femoral access!
- Dr David Deaton joins Endovab
- Clinical results presented at the Veith Symposium!
- Preloaded f-EVAR with pre-lining of fenestrations on table
- Canadian Patent
- Target Drug Delivery
- Endovab obtains further granted patent in Europe
- How do you prevent guidewire entanglement?
Copyright © 2019. Endovascular Development AB. All Rights Reserved.